Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following eligibility criteria to be enrolled in the study:~* Male or female patients 18 years or older~* Previously untreated multiple myeloma diagnosed according to standard criteria requiring systemic treatment~* Patients must have measurable disease~* Nonsecretory multiple myeloma based upon standard M-component criteria (i.e., measurable serum/urine M-component) is not allowed unless the baseline serum free light chain level (Freelite™) is evaluated Patients must meet clinical laboratory criteria as specified in study protocol~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Female and male patients MUST adhere to the guidelines of the lenalidomide pregnancy prevention program~* Must be able to take concurrent aspirin 325 mg daily~* Voluntary written consent~Exclusion Criteria~Patients meeting any of the following exclusion criteria are not to be enrolled in the study:~* Peripheral neuropathy that is greater or equal to Grade 2~* Female patients who are lactating or pregnant~* Major surgery or radiotherapy within 14 days before the first dose of study drug~* Serious infection requiring systemic antibiotic therapy within 14 days before the first dose of study drug~* Diarrhea greater than Grade 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events~* Central nervous system involvement.~* Evidence of current uncontrolled cardiovascular conditions within the past 6 months~* Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection~* Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol~* Known gastrointestinal condition that could interfere with swallowing or the oral absorption or tolerance of ixazomib~* No other prior malignancy within 2 years except nonmelanoma skin cancer or carcinoma in situ of any type if they have undergone complete resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): In phase 1, ixazomib 1.68 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
- Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): In phase 1, ixazomib 2.23 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
- Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): In phase 1, ixazomib 2.97 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
- Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): In phase 1, ixazomib 3.95 mg/m\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
- Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).